Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Tonix pharmaceuticals holding corp. save search
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.03%
C: -5.2%
tnx-2900 fda rare disease treatment pharmaceuticals designation
Binge-eating Disorder Treatment Market Research Report 2024
Published: 2024-02-23 (Crawled : 02:00) - prnewswire.com
VTRS | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: 0.0%
H: 1.93%
C: 1.27%
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 0.0%
H: 4.3%
C: 1.77%
report treatment research market
Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity
Published: 2023-12-04 (Crawled : 12:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 1.91%
H: 2.93%
C: -12.06%
tnx-2900 fda obesity genetic treatment clearance pharmaceuticals trial
Tonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder
Published: 2023-10-31 (Crawled : 21:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: -18.64%
H: 4.15%
C: 2.06%
tnx-601 treatment pharmaceuticals topline results study
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder
Published: 2023-10-16 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 0.33%
H: 2.27%
C: -2.34%
tnx-601 treatment pharmaceuticals study
Tonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family Conference
Published: 2023-10-09 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: -0.28%
H: 4.98%
C: 1.79%
tnx-2900 conference treatment pharmaceuticals research family program
Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain
Published: 2023-10-04 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 2.53%
H: 4.79%
C: 4.09%
tnx-1900 patent oxytocin treatment pharmaceuticals
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder
Published: 2023-09-27 (Crawled : 13:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 2.73%
H: 2.27%
C: -9.15%
tnx-102 defense treatment pharmaceuticals grant trial
Tonix Pharmaceuticals Announces Commitment to Supply Tosymra® (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSK’s Planned Discontinuation of Imitrex® (sumatriptan) Nasal Spray After January 2024
Published: 2023-09-06 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 4.33%
H: 2.15%
C: -1.02%
tosymra treatment pharmaceuticals spray potential migraine
Binge-eating Disorder Treatment Market size is set to grow by USD 578.04 million from 2022 to 2027 | The increasing prevalence of binge-eating disorder drives the market - Technavio
Published: 2023-09-04 (Crawled : 15:30) - prnewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
| Email alert
Add to watchlist
VTRS | $11.25 1.17% 1.16% 4.7M
|
Health Technology
| Email alert
Add to watchlist
treatment set market
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID
Published: 2023-08-07 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 2.05%
H: 10.0%
C: 2.0%
tnx-102 covid treatment pharmaceuticals study
Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder
Published: 2023-07-31 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 4.67%
H: 0.0%
C: 0.0%
tnx-1900 treatment pharmaceuticals study initiated
Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity
Published: 2023-07-10 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 0.63%
H: 8.7%
C: 6.83%
tnx-1900 obesity treatment pharmaceuticals study
A New Depression Drug Being Developed by Tonix May Side-Step Treatment-Limiting Effects of Nearly All Current Antidepressants in the US
Published: 2023-04-27 (Crawled : 15:00) - biospace.com/
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 2.86%
H: 2.0%
C: 1.56%
drug depression
Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit
Published: 2023-03-23 (Crawled : 03:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 0.24%
H: 3.49%
C: 1.26%
tnx-2900 partnership rare disease innovation treatment pharmaceuticals potential
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 2.3%
H: 5.04%
C: 4.24%
tnx-601 treatment pharmaceuticals study major depressive disorder
Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder
Published: 2022-10-03 (Crawled : 07:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 3.0%
H: 12.68%
C: -0.06%
tnx-601 treatment clearance pharmaceuticals potential major depressive disorder
Global Monkeypox Treatment Market to Surpass US$ 258.6 Million by 2030 - Coherent Market Insights
Published: 2022-09-06 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.93%
H: 10.14%
C: 3.79%
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: -1.12%
H: 1.13%
C: -7.65%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
CMRX | $0.8844 -5.14% -5.42% 430K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: -5.88%
treatment monkeypox global market
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID
Published: 2022-08-22 (Crawled : 13:00) - biospace.com/
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: -3.08%
H: 6.35%
C: 3.17%
tnx-102 treatment covid study phase 2
Tonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine Intoxication
Published: 2022-08-02 (Crawled : 17:00) - biospace.com/
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 2.15%
H: 7.37%
C: 0.0%
tnx-1300 treatment drug grant
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.